According to a corporate media release, a company called Spectrum Pharmaceuticals has initiated enrollment of an additional 150 patients into a Phase IIb trial of a new LHRH receptor antagonist called ozarelix (a drug with a similar mechanism of action to degarelix or Firmagon) for the treatment of advanced forms of prostate cancer. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: antagonist, LHRH, ozarelix | 2 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site
